As we near the end of the discussion, I'd like to discuss adnexanet alpha relative to other new reversal agents.
A recent correspondence to the NEJM described a new agent, PER977, that binds and reverses edoxaban. This agent is not specific to factor Xa inhibitors and has potential for use in dabigatran as well. While this agent has not been studied in healthy volunteers yet, it seems to have significant potential. Perhaps we can discuss how they are similar, and where they differ.
Dr. Ansell, perhaps you can discuss PER977, since you were the lead author on the NEJM correspondence.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.